Pathak Ranjan, Amini Arya, Hill Addie, Massarelli Erminia, Salgia Ravi
Department of Medical Oncology and Therapeutics Research, City of Hope, Duarte, CA 91010, USA.
Department of Radiation Oncology, City of Hope, Duarte, CA 91010, USA.
Cancers (Basel). 2021 Jul 7;13(14):3407. doi: 10.3390/cancers13143407.
Immune checkpoint inhibitors have revolutionized the treatment landscape for patients with non-small cell lung cancers. Existing treatment paradigms for brain metastases in lung cancer patients leave patients with adverse neurocognitive function, poor quality of life, and dismal prognosis, thus highlighting the need to develop more effective systemic therapies. Although data are limited, emerging knowledge suggests promising activity and safety of immune checkpoint inhibitors in brain metastases in non-small cell lung cancer patients. This review aims to summarize the current data, highlight the challenges of incorporating immune checkpoint inhibitors in treating these patients, and identify areas for future research.
免疫检查点抑制剂彻底改变了非小细胞肺癌患者的治疗格局。肺癌患者脑转移的现有治疗模式使患者出现不良神经认知功能、生活质量差和预后不佳的情况，因此凸显了开发更有效全身治疗方法的必要性。尽管数据有限，但新出现的知识表明免疫检查点抑制剂在非小细胞肺癌患者脑转移中的活性和安全性颇具前景。本综述旨在总结当前数据，强调将免疫检查点抑制剂纳入这些患者治疗中的挑战，并确定未来研究的领域。
